Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NYSE MKT LLC
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

CVM:US

1.1400 USD 0.0600 5.56%

As of 20:04:08 ET on 03/03/2015.

Snapshot for CEL-SCI Corp (CVM)

Open: 1.1900 Day's Range: 1.1100 - 1.2200 Volume: 1,952,187
Previous Close: 1.0800 52wk Range: 0.5400 - 1.9000 1-Yr Rtn: +4.59%

Stock Chart for CVM

No chart data available.
  • CVM:US 1.1400
  • 1D
  • 1M
  • 1Y
1.0800
Interactive CVM Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for CVM

Current P/E Ratio (ttm) -
Estimated P/E(09/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.5312
Est. EPS (USD) (09/2015) -0.3900
Est. PEG Ratio -
Market Cap (M USD) 104.36
Shares Outstanding (M) 91.54
30 Day Average Volume 736,728
Price/Book (mrq) 8.8091
Price/Sale (ttm) 284.6523
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/13/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for CVM

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for CVM

CEL-SCI Corporation researches and develops certain drugs and vaccines. The Company's Multikine is being tested to determine if it is effective in improving the immune response of cancer patients. CEL-SCI is also developing other products. The Company is currently targeting diseases such as AIDS, herpes simplex, malaria, tuberculosis, prostate cancer, and breast cancer.

Maximilian De ClaraPresident/FounderGeert R KerstenCEO/Treasurer
Eyal TalorChief Scientific OfficerPatricia B PrichepSenior VP:Operations/Secy
More Company Profile & Key Executives for CVM

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil